This 2019 study analyzed data from two Phase III trials involving 1,162 patients with mild to moderate Alzheimer's disease (AD) to assess the relationship between hydromethylthionine (LMTM) plasma concentration and clinical outcomes. Findings revealed that even at a low dose of 8 mg/day, patients with higher plasma levels experienced significant
